201 related articles for article (PubMed ID: 15769928)
41. Update on aromatase inhibitors in breast cancer.
Gould RE; Garcia AA
Curr Opin Obstet Gynecol; 2006 Feb; 18(1):41-6. PubMed ID: 16493259
[TBL] [Abstract][Full Text] [Related]
42. Purpuric drug eruption with leukocytoclastic vasculitis due to gefitinib.
Uchimiya H; Higashi Y; Kawai K; Kanekura T
J Dermatol; 2010 Jun; 37(6):562-4. PubMed ID: 20536674
[No Abstract] [Full Text] [Related]
43. Aromatase inhibitor-associated arthralgia syndrome.
Burstein HJ
Breast; 2007 Jun; 16(3):223-34. PubMed ID: 17368903
[TBL] [Abstract][Full Text] [Related]
44. Leukocytoclastic vasculitis due to thalidomide in multiple myeloma.
Yildirim ND; Ayer M; Küçükkaya RD; Alpay N; Mete O; Yenerel MN; Yavuz AS; Nalçaci M
Jpn J Clin Oncol; 2007 Sep; 37(9):704-7. PubMed ID: 17709605
[TBL] [Abstract][Full Text] [Related]
45. Aromatase inhibitors in breast cancer: an overview.
Altundag K; Ibrahim NK
Oncologist; 2006 Jun; 11(6):553-62. PubMed ID: 16794235
[TBL] [Abstract][Full Text] [Related]
46. Image Gallery: Purpuric fixed drug eruption from ornidazole showing leukocytoclastic vasculitis.
Özkaya E; Büyükbabani N; Erbudak Dinç E
Br J Dermatol; 2017 Oct; 177(4):e164. PubMed ID: 29052870
[No Abstract] [Full Text] [Related]
47. Zoledronic acid prevents cancer treatment-induced bone loss in premenopausal women receiving adjuvant endocrine therapy for hormone-responsive breast cancer: a report from the Austrian Breast and Colorectal Cancer Study Group.
Gnant MF; Mlineritsch B; Luschin-Ebengreuth G; Grampp S; Kaessmann H; Schmid M; Menzel C; Piswanger-Soelkner JC; Galid A; Mittlboeck M; Hausmaninger H; Jakesz R;
J Clin Oncol; 2007 Mar; 25(7):820-8. PubMed ID: 17159195
[TBL] [Abstract][Full Text] [Related]
48. Leukocytoclastic vasculitis: another coumarin-induced hemorrhagic reaction.
Tamir A; Wolf R; Brenner S
Acta Derm Venereol; 1994 Mar; 74(2):138-9. PubMed ID: 7911622
[TBL] [Abstract][Full Text] [Related]
49. Aromatase inhibitor-associated arthralgias.
Chlebowski RT
J Clin Oncol; 2009 Oct; 27(30):4932-4. PubMed ID: 19752332
[No Abstract] [Full Text] [Related]
50. Flurbiprofen and cutaneous vasculitis.
Wei N
Ann Intern Med; 1990 Apr; 112(7):550-1. PubMed ID: 2138443
[No Abstract] [Full Text] [Related]
51. Leukocytoclastic vasculitis masquerading as hand-foot syndrome in a patient treated with sorafenib.
Chung NM; Gutierrez M; Turner ML
Arch Dermatol; 2006 Nov; 142(11):1510-1. PubMed ID: 17116852
[No Abstract] [Full Text] [Related]
52. [Eruption of purpura compatible with vasculitis and torasemide].
Sanfélix Genovés J; Benlloch Nieto H; Verdú Tárraga R; Costa Alcaraz AM
Aten Primaria; 1998 Mar; 21(4):252-3. PubMed ID: 9607256
[No Abstract] [Full Text] [Related]
53. Cutaneous vasculitis induced by paroxetine.
Margolese HC; Chouinard G; Beauclair L; Rubino M
Am J Psychiatry; 2001 Mar; 158(3):497. PubMed ID: 11230000
[No Abstract] [Full Text] [Related]
54. Procainamide-induced urticarial vasculitis.
Knox JP; Welykyj SE; Gradini R; Massa MC
Cutis; 1988 Nov; 42(5):469-72. PubMed ID: 2973973
[TBL] [Abstract][Full Text] [Related]
55. The potential adverse effects of aromatase inhibitors on wound healing: in vitro and in vivo evidence.
Howgate DJ; Gamie Z; Panteliadis P; Bhalla A; Mantalaris A; Tsiridis E
Expert Opin Drug Saf; 2009 Sep; 8(5):523-35. PubMed ID: 19645634
[TBL] [Abstract][Full Text] [Related]
56. [Urticarian vasculitis. A case report after sulfamethoxazoletriméthoprime ingestion].
Feiza BA; Samy F; Asma D; Rym B; Insaf M
Tunis Med; 2005 Nov; 83(11):714-6. PubMed ID: 16422373
[TBL] [Abstract][Full Text] [Related]
57. Optimizing adjuvant endocrine therapy in postmenopausal women with early-stage breast cancer: a decision analysis.
Punglia RS; Kuntz KM; Winer EP; Weeks JC; Burstein HJ
J Clin Oncol; 2005 Aug; 23(22):5178-87. PubMed ID: 15998905
[TBL] [Abstract][Full Text] [Related]
58. Acenocoumarol and vasculitis: a case report.
Aouam K; Gassab A; Khorchani H; Bel Hadj Ali H; Amri M; Boughattas NA; Zili JE
Pharmacoepidemiol Drug Saf; 2007 Jan; 16(1):113-4. PubMed ID: 16981216
[TBL] [Abstract][Full Text] [Related]
59. Bone loss in patients with breast cancer receiving aromatase inhibitors and associated treatment strategies.
Coleman RE; Body JJ; Gralow JR; Lipton A
Cancer Treat Rev; 2008; 34 Suppl 1():S31-42. PubMed ID: 18486346
[TBL] [Abstract][Full Text] [Related]
60. Captopril and vasculitis.
Miralles R; Pedro-Botet J; Farré M; Rubiés-Prat J
Ann Intern Med; 1988 Sep; 109(6):514. PubMed ID: 2970817
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
